Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Status:
Terminated
Trial end date:
2018-08-20
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour
activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants
with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The
primary objective is objective response rate.